BDKRB1 and Alzheimer disease: Moreover, pharmacological or genetic blockade of the B1R abrogated the cognitive deficits induced by a single i.c.v. injection of Aβ1–40 in rodents [18], suggesting that B1R could represent a target for AD therapy.